1. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome
- Author
-
Marieke Heisen, Nisreen Shamseddine, Xingyue Huang, Katharina Verleger, Kevin P. Moore, Khurram Jamil, Shelby Corman, Rachel Bakker, Nehemiah Kebede, Andrew S. Allegretti, Christine Maï, Linlin Luo, and Roberta Leonardi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Hepatorenal Syndrome ,medicine.medical_treatment ,Renal function ,Liver transplantation ,Gastroenterology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Hepatorenal syndrome ,Renal Dialysis ,Terlipressin in Hepatorenal Syndrome ,Internal medicine ,medicine ,Humans ,Vasoconstrictor Agents ,Pharmacology (medical) ,030212 general & internal medicine ,Adverse effect ,Dialysis ,Aged ,Creatinine ,Hepatology ,business.industry ,Acute kidney injury ,Middle Aged ,medicine.disease ,United Kingdom ,Liver Transplantation ,Treatment Outcome ,chemistry ,Female ,Original Article ,030211 gastroenterology & hepatology ,business ,Terlipressin ,medicine.drug - Abstract
Summary Background Hepatorenal syndrome and acute kidney injury are common complications of decompensated cirrhosis, and terlipressin is recommended as first‐line vasoconstrictor therapy. However, data on its use outside of clinical trials are lacking. Aims To assess practice patterns and outcomes around vasoconstrictor use for hepatorenal syndrome in UK hospitals. Methods This was a multicentre chart review study. Data were extracted from medical records of patients diagnosed with hepatorenal syndrome and treated by vasoconstrictor drugs between January 2013 and December 2017 at 26 hospitals in the United Kingdom. The primary outcome was improvement of kidney function, defined as complete response (serum creatinine improved to ≤1.5 mg/dL), partial response (serum creatinine reduction of ≥20% but >1.5 mg/dL) and overall response (complete or partial response). Other outcomes included need for dialysis, mortality, liver transplantation and adverse events. Results Of the 225 patients included in the analysis, 203 (90%) were treated with terlipressin (median duration, 6 days; range: 2‐24 days). Mean (±standard deviation) serum creatinine at vasopressor initiation was 3.25 ± 1.64 mg/dL. Terlipressin overall response rate was 73%. Overall response was higher in patients with mild acute kidney injury (baseline serum creatinine
- Published
- 2020